CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
Jonathan H ShepherdKarla BallmanMei-Yin C PolleyJordan D CampbellCheng FanSara SelitskyAranzazu Fernandez-MartinezJoel S ParkerKatherine A HoadleyZhiyuan HuYan LiMatthew G SolowayPatricia A SpearsBaljit SinghSara M TolaneyGeorge SomloDavid N AndersonCynthia X MaCharles KuzmaEleftherios MamounasMehra GolshanJennifer R BellonDeborah E CollyarOlwen M HahnClifford A HudisEric P WinerAnn H PartridgeTerry HyslopLisa Anne CareyCharles M PerouWilliam M SikovPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Despite higher pCR rates, neither carboplatin nor bevacizumab appeared to improve LTOs although the study was not powered to assess these secondary end points. pCR was associated with superior LTOs even when compared with minimal RD. Markers of immune activation in pretreatment tumor biopsies were independently associated with higher pCR rates and improved survival.